Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1767861 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL690750 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL8675920 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL324428 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL615639 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL4741906 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL1929473 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| SCHEMBL25341592 | 0.94 | CPB2 (0.58) | CPB2CA2GRIK1GRIK2GPR84 | |
| SCHEMBL571313 | 0.94 | CPB2 (0.58) | CPB2CA2GRIK1GRIK2GPR84 | |
| SCHEMBL19148651 | 0.94 | CPB2 (0.58) | CPB2CA2GRIK1GRIK2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101805340-A | Beta-chain simulative and methods involving thereof | CHOONGWAE PHARMA CORP | 2010-08-18 | — | — | CN | disclosed |
| US-7662960-B2 | Beta-strand mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-02-16 | — | — | US | disclosed |
| EP-1646633-B1 | BETA-STRAND MIMETICS | CHOONGWAE PHARMA CORP (KR) | 2009-04-15 | — | — | EP | disclosed |
| CN-1802378-A | Beta-strand mimetics and methods relating thereto | CHOONGWAE PHARMA CORP (KR) | 2006-07-12 | — | — | CN | disclosed |
| EP-1646633-A1 | BETA-STRAND MIMETICS AND METHOD RELATING THERETO | Choongwae Pharma Corporation (KR) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004108731-A1 | BETA-STRAND MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2004-12-16 | — | — | WO | disclosed |
| US-20040053331-A1 | Beta-strand mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2004-03-18 | — | — | US | disclosed |
| WO-1996011196-A1 | PYRAZOLYLMETHYL-THIAZOLIDINES USEFUL AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053331-A1 | Beta-strand mimetics and method relating thereto | BIRC5, BIRC7, XIAP | CPB2 221/4885CA2 3091/4885GRIK1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.